Thalidomide News and Research

RSS
Thalidomide is a drug that is used to treat multiple myeloma in patients who have just been diagnosed, and a painful skin disease related to leprosy. It is also being studied in the treatment of other types of cancer. Thalidomide belongs to the family of drugs called angiogenesis inhibitors. Also called Thalomid.
Three-drug combination produces better results in multiple myeloma patients

Three-drug combination produces better results in multiple myeloma patients

Study reveals why survival for blood cancer patients still varies between regions within Europe

Study reveals why survival for blood cancer patients still varies between regions within Europe

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Tel Aviv University pinpoints mechanism that causes rare and severe congenital syndrome

Tel Aviv University pinpoints mechanism that causes rare and severe congenital syndrome

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Combination of anti-nausea drug and turmeric spice target cancer cells

Combination of anti-nausea drug and turmeric spice target cancer cells

Researchers develop new method that creates libraries of drug candidates, accelerate drug discovery

Researchers develop new method that creates libraries of drug candidates, accelerate drug discovery

Preclinical study reveals pomalidomide shows promising results for treatment of CNS lymphoma

Preclinical study reveals pomalidomide shows promising results for treatment of CNS lymphoma

Janssen receives EC approval to use VELCADE as induction therapy in patients with multiple myeloma

Janssen receives EC approval to use VELCADE as induction therapy in patients with multiple myeloma

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

European Commission amends marketing authorisation for Celgene's REVLIMID

European Commission amends marketing authorisation for Celgene's REVLIMID

New combination therapies with anti-sickling capabilities needed for sickle cell disease

New combination therapies with anti-sickling capabilities needed for sickle cell disease

National Birth Defects Prevention Network honors BU researcher with Godfrey P. Oakley, Jr., Award

National Birth Defects Prevention Network honors BU researcher with Godfrey P. Oakley, Jr., Award

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Researchers determine precise configuration of humulones

Researchers determine precise configuration of humulones

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

Lenalidomide effective alternative in lupus

Lenalidomide effective alternative in lupus